A Study of Intravenous EEDVsMit in Children With Recurrent / Refractory Solid or CNS Tumours Expressing EGFR

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 13% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 11% of the time (918 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-12-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients musttherapyrecurrentmridisease
  Phrases that lowered it: disordersingleopen labelinvestigatordose
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Drug's FAERS reports with a death: 34.8% (raises risk) · Drug's FDA history
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports marked serious: 97.6% (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 2310 (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 271 (raises risk) · Drug's FDA history
• Maximum age: 21 (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors NCT02596503 · started 2015 · scored riskier than 33% of active trials completed
• A Trial of Everolimus and Bevacizumab in Children With Recurrent Solid Tumors NCT00756340 · started 2008 · scored riskier than 57% of active trials completed
• Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma NCT00883688 · started 2009 · scored riskier than 94% of active trials completed
• Phase 2 Study of Sym004 for Adult Patients With Recurrent Glioblastoma NCT02540161 · started 2016 · scored riskier than 99% of active trials completed
• Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors NCT01259479 · started 2010 · scored riskier than 64% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.